Turkey-based digital well being startup h2o therapeutics introduced its new Apple Watch-enabled freezing of gait-cuing characteristic, dubbed Foggy, designed for Parkinson’s Illness sufferers has obtained FDA itemizing as a Class II medical system and is accessible through prescription.
Based on the Parkinson’s Basis, freezing of gait is a symptom of Parkinson’s Illness during which a affected person experiences a brief, involuntary incapability to maneuver. Freezing can also have an effect on an individual’s speech or different components of the physique.
h2o therapeutics is an organization that deploys augmented actuality, AI and mobile-based digital therapeutics. The corporate additionally affords an early-detection COVID-19 smartwatch system named Covie.
Foggy makes use of the Taptic Engine in an Apple Watch to supply vibrotactile stimulation when a affected person is experiencing freezing of gait. Customers faucet a complication that initiates suggestions to help with the situation.
The characteristic is accessible by the corporate’s Parky app, which is accessible for Apple Watch customers by prescription.
“Cueing methods maintain immense promise in aiding people with freezing of gait. Nonetheless, the important thing to their effectiveness lies in accessibility, individualization, and ease of use. Our introduction of Foggy marks a major development within the discipline, providing sufferers a non-invasive answer by merely sporting their Apple Watch, designed to help with out including cognitive load,” Yagmur Selin Gulmus, founding father of h2o therapeutics, stated in an announcement.
THE LARGER TREND
Parky obtained FDA clearance in 2022. The appliance screens Parkinson’s signs, resembling tremors and dyskinesia.
h2o therapeutics partnered with AmerisourceBergen in 2023 to convey the corporate’s Parky app to market.
AmerisourceBergen supported h2o integration into well being programs and helped generate affected person engagement by AmerisourceBergen’s digital therapeutics platform. The DTx platform permits physicians to order and fulfill digital therapeutics.
Different corporations within the wearable monitoring market embody Washington-based NeuroRPM and brain-data startup Rune Labs.
Rune Labs locked down FDA clearance for its Parkinson’s symptom monitoring app, referred to as StrivePD, in 2022. The appliance additionally makes use of Apple Watch monitoring capabilities to trace uncontrolled physique motion.
Rune Labs partnered with biopharma analysis firm BlueRock Therapeutics in 2023 to additional examine Parkinson’s Illness utilizing Rune Labs StriveStudy medical platform and the corporate’s monitoring app StrivePD.
NeuroRPM gained FDA clearance in 2023 for a Parkinson’s monitoring app that leverages AI to observe widespread Parkinson’s signs resembling tremors and bradykinesia.
